Table 2.
Anti-proliferate activity of PHA-767491 in multiple myeloma primary samples with diverse genetic and molecular features. Primary myeloma tumor cells isolated from patients were treated with increasing amount of PHA-767491. Cell viability was examined by CellTiter Glo 48 h after drug treatment. The IC50 was calculated using GraphPad Prism.
| Primary Sample | Cytogenetics | ISS | mSMART | Prior Rx | PHA-767491 IC50 (μM) |
|---|---|---|---|---|---|
| GAL-MM-1 | Tetraploid, 13q | Stage 3 | High Risk | MPT/V/R/D | 3 |
| GAL-MM-2 | Clonal Evolution. t(11;14) | Stage 3 | High Risk | VMPT/ASCT | 2 |
| GAL-MM-3 | t(4; 14) | Stage 3 | High Risk | VRD/ASCT | 1.9 |